Backed by the impressive data from the EMPEROR-Preserved trial, Boehringer Ingelheim GmbH and Eli Lilly and Company are busy preparing supplementary filings for Jardiance which if successful – as seems highly likely – will become the only therapy to improve outcomes in all heart failure patients, regardless of ejection fraction or diabetes status.
Jardiance (empagliflozin) took center stage at the recent virtual European Society of Cardiology meeting, with results from the 5,988-patient study showing that the SGLT-2 inhibitor plus standard of care demonstrated a 21% reduction for the composite primary endpoint of cardiovascular death or hospitalization
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
